We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

170 hedge funds and large institutions have $3.23B invested in Blueprint Medicines in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 39 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 12

236% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $5.63M

85% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 39

28% more capital invested

Capital invested by funds: $2.53B → $3.23B (+$703M)

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

23% more funds holding

Funds holding: 138 → 170 (+32)

6.93% more ownership

Funds ownership: 92.75% → 99.69% (+6.9%)

Holders
170
Holders Change
+32
Holders Change %
+23.19%
% of All Funds
3.86%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.23%
New
44
Increased
72
Reduced
39
Closed
12
Calls
$18.9M
Puts
$5.63M
Net Calls
+$13.3M
Net Calls Change
+$12.4M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$97.3M
2
HIM
Hillhouse Investment Management
Cayman Islands
+$54.1M
3
PA
Perceptive Advisors
New York
+$50.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$39.7M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.6M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$53.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$52M
3
CCM
Cadian Capital Management
New York
-$21.9M
4
BI
BVF Inc
California
-$16.9M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$14.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$25.9M +$20M +283,972 +473%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$22.5M -$1.28M -18,191 -6%
DCM
28
Driehaus Capital Management
Illinois
$21.2M +$6.71M +95,325 +51%
BC
29
Boxer Capital
California
$18.9M – – –
TA
30
Teachers Advisors
New York
$18.4M +$334K +4,754 +2%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$14.6M +$1.26M +17,908 +10%
Charles Schwab
32
Charles Schwab
California
$14.2M +$1.37M +19,485 +12%
Jennison Associates
33
Jennison Associates
New York
$13.6M -$3.41M -48,532 -21%
Goldman Sachs
34
Goldman Sachs
New York
$12.4M -$4.29M -61,034 -27%
EAM
35
Eventide Asset Management
Massachusetts
$11.3M -$6.05M -86,000 -36%
GTC
36
Ghost Tree Capital
New York
$11.3M +$10.6M +150,000 New
RSCM
37
Rock Springs Capital Management
Maryland
$11M +$4.22M +60,000 +69%
SH
38
Sandia Holdings
Connecticut
$10.2M -$2.55M -36,237 -21%
TCIM
39
TIAA CREF Investment Management
New York
$8.72M -$117K -1,665 -1%
Deutsche Bank
40
Deutsche Bank
Germany
$8.54M +$4.02M +57,102 +102%
UBS AM
41
UBS AM
Illinois
$8.28M +$79.2K +1,125 +1%
DCM
42
DAFNA Capital Management
California
$7.59M +$1.74M +24,691 +32%
AG
43
Artal Group
Luxembourg
$7.54M +$7.04M +100,000 New
MIM
44
Monashee Investment Management
Massachusetts
$7.18M – – –
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$6.2M +$5.13M +72,953 +793%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$6.14M +$2.7M +38,400 +89%
OA
47
Omega Advisors
New York
$5.66M +$5.28M +75,000 New
SEI Investments
48
SEI Investments
Pennsylvania
$5.62M +$1.07M +15,257 +26%
LCM
49
Laurion Capital Management
New York
$5.5M +$4.2M +59,690 +450%
Alyeska Investment Group
50
Alyeska Investment Group
Illinois
$5.32M -$2.08M -29,509 -30%
1
2
3 4 5

BPMC Hedge Fund Activity: Q4 2017 in Review

170 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2017, worth a combined $3.23B — up 28% from $2.53B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new BPMC positions and 12 closed out — a net gain of 32 holders — while 72 added to existing stakes and 39 trimmed.

The largest buyer was Vanguard Group, adding an estimated $97.3M. The largest seller was PFM Health Sciences, cutting an estimated $53.6M.

  • 170 institutional investors held Blueprint Medicines (BPMC) as of Q4 2017, up from 138 in Q3 2017.
  • Funds reported $3.23B of Blueprint Medicines stock for Q4 2017, up 28% quarter-over-quarter.
  • 44 funds opened new Blueprint Medicines positions in Q4 2017 and 12 closed out, a net change of +32 holders.
  • The largest Blueprint Medicines buyer in Q4 2017 was Vanguard Group, an estimated $97.3M added.
  • The largest Blueprint Medicines seller in Q4 2017 was PFM Health Sciences, an estimated $53.6M sold.

Based on aggregated 13F filings for Q4 2017.